NCT02182401终止1 期
An Open-label, Fixed Sequence Phase I Study in Healthy Male Volunteers to Assess Sequentially the Effects of Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA, on the Single Dose Pharmacokinetics of Midazolam and Tolbutamide and on the Systemic Exposure of BI 207127 NA and BI 201335 NA
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 37
- 主要终点
- Steady-state AUC (Area under concentration-time curve)
研究概览
简要总结
Study to investigate the pharmacokinetic drug-drug interaction potential of BI 207127 NA and BI 201335 NA on each other at steady-state and to quantify the effect of BI 207127 NA, and BI 207127 NA combined with BI 201335 NA, on the activity of CYP 2C9 and CYP 3A4 using the probe substrates tolbutamide (CYP 2C9) and midazolam (CYP 3A4).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males (caucasian)
- •Age ranging ≥ 21 and ≤ 50 years
- •Body mass index (BMI) ≥ 19 and ≤ 29.9 kg/m2
- •Willing to complete all study-related activities
- •Volunteers give their written informed consent prior to admission to the study
- •Exclusion criteria:
- •Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders, clinically relevant electrolyte disturbances
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of photosensitivity or recurrent rash
- •History of orthostatic hypotension, fainting spells or blackouts
- •Chronic or clinically relevant acute infections
- •History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- •Intake of drugs with a long half-life (> 24:00 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study or during the study
- •Use of any drugs which might influence the results of the trial up to 7 days prior to enrolment in the trial or during the trial
- •vulnerable subjects (that is persons kept in detention)
- •exclusion of contraindications or hypersensitivity to midazolam and / or tolbutamide
- •Participation in another trial with an investigational drug (within two months prior to administration or during the trial)
- •Smoker (> 10 cigarettes or > 3 cigars of > 3 pipes/day)
- •Inability to refrain from smoking on trial days
- •Alcohol abuse (> 60 g/day)
- •Drug abuse
- •Blood donation (> 100 mL within four weeks prior to administration or during the trial)
- •Any laboratory value outside the reference range if indicative of underlying disease or poor health
- •Excessive physical activities within the last week before the trial or during the trial
- •Hypersensitivity to treatment medication and/or related drugs of these classes
- •A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTcF, or QTcB interval >450 ms)
- •Homozygous carriers of the UGT1A1 (uridine diphosphate glucuronosyltransferase 1A1) enzyme polymorphism *28 and *60
排除标准
- 未提供
研究组 & 干预措施
BI 207127 NA
Experimental
fixed sequence
干预措施: BI 207127 NA (Drug)
BI 207127 NA
Experimental
fixed sequence
干预措施: BI 201335 NA (Drug)
BI 207127 NA
Experimental
fixed sequence
干预措施: Midazolam (Drug)
BI 207127 NA
Experimental
fixed sequence
干预措施: Tolbutamide (Drug)
结局指标
主要结局
Steady-state AUC (Area under concentration-time curve)
时间窗: up to day 31
Steady-state Cmax (Maximum measured concentration of the analyte in plasma)
时间窗: up to day 31
次要结局
- AUC for several time points(up to day 31)
- t1/2 (Terminal half-life of the analyte in plasma)(up to day 31)
- Cavg0-24(up to day 31)
- Ratio for Cmax,Met at several time points(up to day 31)
- Ratio for AUC at several time points(up to day 31)
- Tlast,N(up to day 31)
- Cmax for several time points(up to day 31)
- CL/F (Total apparent clearance of the analyte in plasma following extravascular administration) for several time points(up to day 31)
- V/F (Apparent volume of distribution during following an extravascular dose) for several time points(up to day 31)
- Tmax (Time from dosing to the maximum measured concentration of the analyte in plasma)(up to day 31)
- Cx for several time points(up to day 31)
- CLR (renal clearance of the analyte for different time points)(up to day 29)
- Number of patients with adverse events(up to 66 days)
- Assessment of tolerability on a 4-pointe scale by investigator(within 14 days after last drug administration)
- fe (fraction of analyte eliminated in urine for different time points)(up to day 29)
- Ae (amount of analyte eliminated in urine for different time points)(up to day 29)
研究者
相似试验
已完成
1 期
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected PatientsHepatitis C, ChronicNCT01525628Boehringer Ingelheim72
已完成
2 期
BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive TreatmentLeukemia, Myeloid, AcuteNCT00632749Boehringer Ingelheim68
已完成
1 期
Bioavailability of BI 10773 and Pioglitazone in Healthy Male VolunteersHealthyNCT02276365Boehringer Ingelheim20
已完成
1 期
Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants.HealthyNCT01978652Biogen44
已完成
1 期
Single Rising Oral Doses of BI 10773 in Healthy Male VolunteersHealthyNCT02182453Boehringer Ingelheim48